Graft Polymer UK CEO on drug delivery collaboration with Awakn Life Sciences [Video]

Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive’s Stephen Gunnion about a commercial collaboration with Awakn Life Sciences following the company’s strategic operational review.

Tennyson outlined Graft Polymer’s decision to exit the industrial plastics sector to focus on its innovative biopolymer drug delivery systems. This pivot, driven by macroeconomic challenges, aims to stabilise and grow the business by targeting high-potential sectors such as substance use disorder and mental health treatments. The company recently completed a £1.8 million recapitalization to support this new focus.

Tennyson explained the rationale behind selecting Awakn Life Sciences for its first commercial collaboration, highlighting the quality of Awakn’s scientific team, particularly Professor David Nutt, the robustness of its scientific programs, and the promising pipeline of treatments for trauma-related disorders like PTSD. Graft Polymer secured a 40% stake in the future net income of Awakn’s high-potential pre-clinical asset, emphasising the significant market opportunities in North America and Europe.

“We believe the potential benefit for Graft shareholders is interesting and material,” Tennyson added.
For more videos, visit Proactive’s YouTube channel, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content.

#GraftPolymer #AwaknLifeSciences #Biopolymer #DrugDelivery #MentalHealth #PTSDTreatment #Pharmaceuticals #Biotech #Investment #healthcareinnovation #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews